The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma

Table 3

Clinical molecular factors for progression-free and overall survival in all patients () and patients with known L858R mutation () by univariate analysis.

	All cases ()				Patients with known L858R mutation ()
	Progression-free survival		Overall survival		Progression-free survival		Overall survival
	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Age (y)	1.2 (0.7–1.8)	0.56	1.4 (0.8–2.2)	0.32	1.2 (0.6–2.5)	0.7	1.1 (0.5–2.2)	0.8
Gender	1.4 (0.9–2.2)	0.14	1.3 (0.8–2.3)	0.22	1.5 (0.8–2.7)	0.4	1.6 (0.8–2.9)	0.4
PS >2	2.9 (1.3–6.1)	0.02	6.8 (2.9–11.5)	<0.001	5.4 (1.6–12.5)	0.01	12.1 (6.7–15)	<0.001
Smoking	2.3 (1.3–3.7)	0.03	2.3 (1.2–3.8)	0.01	3.7 (1.5–7.5)	0.01	3.3 (1.1–7.2)	0.001
2nd-line C/T	2.1 (1.6–4.9)	0.01	2.3 (1.4–4.7)	0.01	3.9 (1.7–6.8)	0.001	4.3 (2.0–8.7)	0.001
EGFR mutation (L858R)	2.4 (1.3–5.6)	0.02	2.1 (1.4–4.9)	0.01	—	—	—	—

EGFR: epidermal growth factor receptor gene; HR: hazard ratio; CI: confidence interval; PS: performance status; C/T: chemotherapy; values were obtained by log-rank test.